Osimertinib in Pulmonary Manifestations: Two Case Reports and Review of the Literature

Por LU, HANNAH, DOWELL, JONATHAN
Publicado no In Vivo (2020)

UKCAT and medical student selection in the UK – what has changed since 2006?

Por Greatrix, Rachel, Dowell, Jonathan
Publicado no BMC Med Educ (2020)

Small-Cell Lung Cancer: Translational Research Enroute to Therapeutic Advances

Por Dowell, Jonathan, Minna, John D.
Publicado em 2008

Modern management of malignant pleural mesothelioma

Por Patel, Shivani C, Dowell, Jonathan E
Publicado no Lung Cancer (Auckl) (2016)

Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date

Por Levin, Pavel A, Dowell, Jonathan E
Publicado no Onco Targets Ther (2017)

Beyond ‘health and safety’ – the challenges facing students asked to work outside of their comfort, qualification level or expertise on medical elective placement

Por Wiskin, Connie, Dowell, Jonathan, Hale, Catherine
Publicado no BMC Med Ethics (2018)

Widening access to UK medical education for under-represented socioeconomic groups: modelling the impact of the UKCAT in the 2009 cohort

Por Tiffin, Paul A, Dowell, Jonathan S, McLachlan, John C
Publicado em 2012

The UKCAT-12 study: educational attainment, aptitude test performance, demographic and socio-economic contextual factors as predictors of first year outcome in a cross-sectional co...

Por McManus, I C, Dewberry, Chris, Nicholson, Sandra, Dowell, Jonathan S
Publicado em 2013

Predictive validity of the UK clinical aptitude test in the final years of medical school: a prospective cohort study

Por Husbands, Adrian, Mathieson, Alistair, Dowell, Jonathan, Cleland, Jennifer, MacKenzie, Rhoda
Publicado em 2014

Cellular stress mechanisms of prenatal maternal stress: heat shock factors and oxidative stress

Por Dowell, Jonathan, Elser, Benjamin A, Schroeder, Rachel E, Stevens, Hanna E
Publicado no Neurosci Lett (2019)

Looking Beyond Surveillance, Epidemiology, and End Results: Patterns of Chemotherapy Administration for Advanced Non-small Cell Lung Cancer in a Contemporary, Diverse Population

Por Rasco, Drew W., Yan, Jingsheng, Xie, Yang, Dowell, Jonathan E., Gerber, David E.
Publicado em 2010

Upper Extremity Venous Thrombosis in Patients With Cancer With Peripherally Inserted Central Venous Catheters: A Retrospective Analysis of Risk Factors

Por Ahn, Daniel H., Illum, Henrik Bo, Wang, David H., Sharma, Anant, Dowell, Jonathan E.
Publicado em 2013

Construct-level predictive validity of educational attainment and intellectual aptitude tests in medical student selection: meta-regression of six UK longitudinal studies

Por McManus, IC, Dewberry, Chris, Nicholson, Sandra, Dowell, Jonathan S, Woolf, Katherine, Potts, Henry WW
Publicado em 2013

Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapy

Por Gerber, David E., Rasco, Drew W., Le, Phat, Yan, Jingsheng, Dowell, Jonathan E., Xie, Yang
Publicado em 2011

Consent Timing and Experience: Modifiable Factors That May Influence Interest in Clinical Research

Por Gerber, David E., Rasco, Drew W., Skinner, Celette Sugg, Dowell, Jonathan E., Yan, Jingsheng, Sayne, Jennifer R., Xie, Yang
Publicado em 2012

A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511)

Por Owonikoko, Taofeek K., Dahlberg, Suzanne E., Khan, Saad A., Gerber, David E., Dowell, Jonathan, Moss, Rebecca A., Belani, Chandra P., Hann, Christine L., Aggarwal, Charu, Ramalingam, Suresh S.
Publicado no Lung Cancer (2015)

Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial

Por Iyengar, Puneeth, Wardak, Zabi, Gerber, David E., Tumati, Vasu, Ahn, Chul, Hughes, Randall S., Dowell, Jonathan E., Cheedella, Naga, Nedzi, Lucien, Westover, Kenneth D., Pulipparacharuvil, Suprabha, Choy, Hak, Timmerman, Robert D.
Publicado no JAMA Oncol (2017)

Randomized Phase II Trial of Erlotinib in Combination with High Dose-Celecoxib or Placebo in Patients with Advanced Non-small Cell Lung Cancer

Por Reckamp, Karen L., Koczywas, Marianna, Cristea, Mihaela C., Dowell, Jonathan E., Wang, He-Jing, Gardner, Brian, Milne, Ginger L., Figlin, Robert A., Fishbein, Michael C., Elashoff, Robert M., Dubinett, Steven M.
Publicado no Cancer (2015)

A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer

Por Yamamoto, Nobuyuki, Hayashi, Hidetoshi, Planchard, David, Morán, Teresa, Gregorc, Vanesa, Dowell, Jonathan, Sakai, Hiroshi, Yoh, Kiyotaka, Nishio, Makoto, Cortot, Alexis B., Benhadji, Karim A., Soni, Nital, Huang, Jinhong, Makris, Lukas, Cedres, Susana
Publicado no Invest New Drugs (2020)

Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer

Por Gerber, David E., Boothman, David A., Fattah, Farjana J, Dong, Ying, Zhu, Hong, Skelton, Rachel A., Priddy, Laurin L., Vo, Peggy, Dowell, Jonathan E., Sarode, Venetia, Leff, Richard, Meek, Claudia, Xie, Yang, Schiller, Joan H.
Publicado no Lung Cancer (2015)